TNF and inflammatory bowel disease: In addition to accelerating earlier treatment initiation, the cost-effectiveness of biosimilars may also enable patients to continue treatment over a longer period to maintain remission and, as such, biosimilar anti-TNF-α medicines may permit IBD treatment continuity [12].